INNOVATION, HEALTH AND EXPERTISE

Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs, Consumer Health products and Original drugs.

Read More

Our Company

As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs.

We focus on three core activities:

Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe.

Our company
Rx products

RX
PRODUCTS

Since 1990, Stragen has always been committed to the development of Selected and Advanced Generics. As a result…

Consumer health products

CONSUMER HEALTH PRODUCTS

Today’s consumers are more digitally connected and educated about the need for healthier lifestyles than ever before…

Original drugs development

ORIGINAL DRUGS DEVELOPMENT

In its continuous commitment to advancing public health, Stragen invests in the development up to proof…

Innovation

At Stragen, we aspire to be one of the leading innovative partners in health. Innovation is at the heart of everything we do. It is the core function that drives our passionate employees to bring to market high quality innovative drugs and consumer health products. Through our entrepreneurial approach and 30 years of R&D know-how, we have developed a wide range of new products and created opportunities in more than 60 countries.

Years of R&D
Know-How

Worldwide
Affiliates

Market
Authorizations

Operating
Countries

Innovation

Worldwide Presence

Our global network, including 10 affiliates, benefits from Stragen’s decades of experience in hospital and retail market supply. Select your region and find more information through your local website.

Alaxia breaks new ground with lead compound ALX-009 as virucidal agent

Alaxia breaks new ground with lead compound ALX-009 as virucidal agent ALX-009, developed as an antimicrobial drug for antibiotic resistant infections in lungs of Cystic Fibrosis...

Stragen Loves Women

Stragen Loves Women Women’s Day is celebrated globally on March 8th every year in honour of their remarkable contribution to our society. The day also commemorates the inspiring...

CPhI 2019

CPhI 2019 For over 15 years, we have been present during the CPhI worldwide. It is an important opportunity for us to demonstrate our Pharma and Consumer Health portfolio and let...

Stragen at CPhI

Stragen at CPhI From 05.11 until 07.11 we will be at the CPHI Worldwide meeting in Frankfurt, Germany. Come and visit us at booth 60B20, get to know our team and product...

SniZtop® is now available in Romania!

SniZtop® is now available in Romania! SniZtop® has just been launched in Romania with our partner Pharmalink. It’s available in pharmacies and online. SniZtop® in...

Two Gold Prizes for Leviker®

Two Gold Prizes for Leviker® Stragen is proud to announce that Leviker® won not one, but two Gold Prices this summer! Known as NAFLiver in Greece, Leviker® was recognized as...

SniZtop® Gum available in Switzerland!

SniZtop® Gum available in Switzerland! Stragen is proud to announce the first launch of SniZtop®Gum in Switzerland,in exclusivity with our partner...

SniZtop® Gum

SniZtop® Gum Stragen is proud to launch the first chewing gum for fast allergy relief Stragen now offers an innovative and effective form in the treatment of allergy...

SniZtop® is spreading, allergy is not!

SniZtop® is spreading, allergy is not! Stragen is pleased to announce Normon SA, a leading Spanish pharmaceutical company with more than 80 years of experience, integrated...